We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Galectin-3 Associated with Poor Prognosis in Cardiopathy Patients

By LabMedica International staff writers
Posted on 18 Jul 2013
Print article
Image: Galectin-3 test kit (Photo courtesy of BG Medicine Inc.).
Image: Galectin-3 test kit (Photo courtesy of BG Medicine Inc.).
The soluble β-galactoside-binding lectin, galectin-3, is elevated in a substantial portion of patients with heart failure, especially those with more severe disease and renal dysfunction.

Increased levels of circulating galectin-3 may reflect the severity of active myocardial remodeling and adverse outcome as galectin-3 regulates fibrogenesis, inflammation, tissue repair, and cell proliferation.

Scientists and cardiologists at the Veterans Administration Medical Center (Minneapolis, MN, USA) conducted a randomized, placebo-controlled, double-blind, multicenter trial that enrolled 5,010 patients with symptomatic heart failure (HF) to evaluate the efficacy of the angiotensin receptor blocker (ARB) valsartan. They measured galectin-3 and other biomarkers such as high-sensitivity C-reactive protein, high-sensitivity troponin, and B-type natriuretic peptide at three time points in a subpopulation of the trial patients. The time points were at baseline at 4 and 12 months after randomization.

Plasma samples from the patients were analyzed and galectin-3 was measured using an enzyme-linked immunosorbent assay (ELISA) (BG Medicine Inc.; Waltham, MA, USA). Galectin-3 levels at baseline ranged from 4.8 to 53 ng/mL. The median baseline galectin-3 level in 1,650 patients was 16.2 ng/mL, and levels increased significantly from baseline. At 4 months, the level increased by 1.0 ng/mL and by 12 months it had risen by 2.2 ng/mL. Each 1 ng/mL increase in galectin-3 was associated with an estimated 2.9% higher risk of mortality, 2.1% increased risk of first morbid event, and 2.2% greater risk of heart failure hospitalization.

The authors concluded that galectin-3 levels are elevated in a substantial proportion of patients with HF, particularly those with more severe HF and renal impairment. Median galectin-3 levels increased over time, and the magnitude of these serial increases was found to be independently and significantly associated with poorer HF outcomes. In patients with baseline galectin-3 levels below the median, use of valsartan was associated with a significant decrease in hospitalizations for heart failure. The study was published in the May 2013 issue of the European Journal of Heart Failure.

Related Links:
Veterans Administration Medical Center
BG Medicine Inc.

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
New
Mumps Virus Test
ZEUS ELISA Mumps IgG Test System

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.